All News
Factors Associated with COVID-19 Deaths in Rheumatic Patients
Analysis of data from the COVID-19 Global Rheumatology Alliance shows that rheumatic diseases infected with COVID-19 had a greater risk of death with age, comorbidities, high disease activity and few specific therapies.
Read Article
Links:
Links:
RheumNow Podcast – Myth Busters (5.21.2021)
Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com
Read Article
Lower Rates of Serious Infection with Ustekinumab in Psoriatic Disease
Patients with psoriasis or psoriatic arthritis who were being treated with ustekinumab (Stelara) had lower rates of serious hospitalized infections than patients receiving other biologics or small molecule therapies, a study utilizing data from two commercial claims databases found.
Read Article
Tocilizumab Risk of Diverticulitis and GI Perforation
A French registry analysis compared the risk of diverticulitis and gastrointestinal perforation (GIP) in rheumatoid arthritis (RA) patients treated with biologics and found a greater risk of both in patients receiving tocilizumab (TCZ) compared with those on rituximab (RTX) or abatacept (ABA
Read Article
Checkpoint Inhibitor Safety in Melanoma Patients with Autoimmune Disease
Immune checkpoint inhibitors (ICI) are well known to cause immune-related adverse events (irAEs). A study from the Dutch Melanoma Treatment Registry shows that the use of checkpoint inhibitors for advanced melanoma in AID (autoimmune disease) patients did not increase the risk of irAEs, except for those with preexisting IBD.
Read Article
Severity Associated with Erosive Hand Osteoarthritis
Erosive hand osteoarthritis (EHOA) was studied as part of the Osteoarthritis Initiative, and shown to increase with advanced age and female sex, with developmental findings to suggest that EHOA as a disorder of skeletal frailty.
Read Article
IL-23 Inhibitor Tildrakizumab Effective in Psoriatic Arthritis
Tildrakizumab, a monoclonal antibody targeting interleukin-23p19 studied in adults with psoriatic arthritis (PsA), was found to be superior to placebo and well tolerated without reports of uveitis, systemic fungal infections, inflammatory bowel disease, major cardiac events or death.
Read Article
RheumNow Live 2021 Now Available for All
RheumNow Live (RNL) for 2021 was held March 20 - 21 in Fort Worth, TX, and now all can partake in the meeting - by video, podcast or by signing up for Tuesday Nite Rheumatology (TNR).
Read Article
Risk Factors for Rheumatoid Arthritis-associated Interstitial Lung Disease
Sparks and colleagues have published a matched cohort analysis demonstrating risk factors that may augment the risk of rheumatoid arthritis (RA)-associated interstitial lung disease (ILD), especially the combination of obesity, high CRP, high MD-HAQ and >30 pack-year smoking h
Read Article
NSAID Safety with COVID-19 Infection
NSAIDs do not affect COVID outcomes; here we are nearly 16 months into the pandemic, and this is the common sense conclusion of a recent trial published in Lancet Rheumatology.
Read Article
Insurers Bet Big on Bribing Patients
Last month, psoriasis patients covered by Cigna received a curious letter from the insurance giant's pharmacy management division.
Read Article
AURORA-1: Voclosporin Efficacy in Lupus Nephritis
Lancet has published the results of the AURORA-1 trial, wherein the calcineurin inhibitor, voclosporin, was tested in a placebo controlled trial of lupus nephritis and shown to be effective at inducing a complete renal response.
Read Article
FDA Advisors Split on Avacopan for Vasculitis
Members of an FDA advisory panel were sharply divided as to whether avacopan, an oral small molecule inhibitor of the C5a receptor, was sufficiently safe and effective for treating antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
Read Article
Higher Hydroxychloroquine Blood Levels Reduces Thrombosis Risk in Lupus
Petri and colleagues have published that measuring hydroxychloroquine (HCQ) blood levels can be useful in systemic lupus erythematosus (SLE), as low levels are associated with an increased thrombotic risk in SLE.
Read Article
Avacopan for ANCA Vasculitis Goes in Front of the FDA
An FDA advisory panel will consider whether to recommend approval of an oral C5a inhibitor for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, with agency staff raising questions over the "clinical meaningfulness" of key study data.
Read Article
RheumNow Podcast – Falling or Falling in Love?
Dr. Jack Cush reviews the best journal articles from the past week on RheumNow.com.
Read Article
ARTIC REWIND - Don't Half DMARD Therapy
The ARTIC-REWIND study examined rheumatoid arthritis (RA) patients in remission on conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) to see if they could "step-down" their csDMARDs theray; but the study showed that 25% those who went on half-dose experienced disease fl
Read Article
Drug Monitoring Ineffective with Infliximab Treatment
The predictive value of therapeutic drug monitoring (TDM) while on biologics is debateable; gastroenterology routinely relies on TDM, while rheumatologists do not.
Read Article